Author:
Aggarwal Ranjana,Bhattacharya Sujit,Singh Shubham
Abstract
AbstractCOVID-19 has created an unprecedented level of research and innovation activity globally to bring out drug to control or cure the disease, and develop vaccine for long time prevention. A ‘new/better normal’ is emerging that is trying to push this time period for drug development and vaccine within a year and earlier than that from typical 8 to 10 years for drugs and 10 to 15 years for vaccine. This is happening due to multiple factors: strong policy push by different government that includes dedicated investment, speeding up regulation process, multiple agencies involvement, and multilateral bodies led by WHO trying to create a global platform, huge grants from private funding bodies, strategic linkages across the whole research and innovation value chain between firms, academic, research organisations and start-ups.The paper maps the research papers and ongoing clinical trials to provide an informed view of the current status of the research and drug development activity as seen through the lens of research papers and clinical trials. The intended goal of this study is to help the research community and policy makers to keep track of highly relevant research and drug development in COVID-19.
Publisher
Cold Spring Harbor Laboratory
Reference19 articles.
1. COVID-19: a new challenge for human beings;Cellular and Molecular immunology,2020
2. Bhattacharya S , Singh S. Visible Insights of the Invisible Pandemic: A Scientometric, Altmetric and Topic Trend Analysis. 2020. arXiv.2004.100878v1[cs.DL]
3. Implications for Indian pharmaceutical sector in the new WTO regime;Medicinal Chemistry Research,2004
4. Flooded by the torrent: the COVID-19 drug pipeline;The Lancet,2020
5. SARS-CoV-2 Vaccines: Status Report
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献